Novavax (NVAX) shares spiked in the premarket on Thursday after the COVID-19 vaccine maker beat Street forecasts with its Q2 2026 financials and raised its full-year revenue guidance. The Gaithersburg, Maryland-based biotech reported $57M in revenue for the quarter, beatin
Novavax (NVAX) shares spiked in the premarket on Thursday after the COVID-19 vaccine maker beat Street forecasts with its Q2 2026 financials and raised its full-year revenue guidance.
The Gaithersburg, Maryland-based biotech reported $57M in revenue for the quarter, beating the estimates by $3.7M
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
